Intellia began a rolling FDA submission for lonvoguran ziclumeran (lonvo-z) Monday after phase 3 data showed a single infusion reduced hereditary angioedema attacks by 87% versus placebo.
The Haelo trial enrolled 80 patients. At six months, 62% of lonvo-z patients were attack-free and off therapy entirely, against 11% in the placebo arm. William Blair had pegged the bull case at 90% attack reduction; Intellia cleared the analysts’ 80% base case, and the analysts called lonvo-z a “compelling one-time option.”
HAE is a rare genetic condition marked by recurrent, potentially life-threatening swelling. All existing drugs (Takeda’s Takhzyro, Ionis’ Dawnzera, BioCryst’s Orladeyo) require ongoing dosing. Lonvo-z uses CRISPR to inactivate the gene that produces bradykinin, and could end the disease after one treatment.
That’s the pitch. The commercial reality is harder. BioMarin pulled its hemophilia gene therapy Roctavian after failing to displace Roche’s Hemlibra — a lesson the HAE field won’t forget. Intellia also carries a safety cloud: a patient died last year after receiving nex-z, a separate Intellia therapy, and Guggenheim warned that lonvo-z may face commercial headwinds even though the clinical hold didn’t apply.
Lonvo-z’s phase 3 safety data were clean: infusion-related reactions, headache, and fatigue, all mild or moderate, with no serious adverse events. One patient had a grade 2 liver enzyme elevation that resolved spontaneously within a week.
Intellia aims to complete the rolling submission in the second half of this year, targeting a first-half 2027 launch.
— Sarah Chen